References
- Huggins C, Hodges CV. The effect of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 43: 209–12
- Collins WP, Mansfield MD, Alladina NS, Sommerville IF. Radioimmunoassay of plasma testosterone. J Steroid Biochem 1972; 3: 333–48
- Blackard CE, Doe RP, Mellinger GT, Byar DP. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 1970; 26: 249–56
- The Veterans Administration Cooperative Urological Research Group. Carcinoma of prostate: treatment comparisons. J Urol 1967; 98: 516–22
- Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126–30
- Bailar JC 3rd, Byar DP. Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970; 26: 257–61
- Clark P, Houghton L. Sub capsular orchidectomy for carcinoma of the prostate. Br J Urol 1977; 49: 419–25
- Tolis G, Mehta A, Comaru-Schally AM, Schally AV. Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. J Clin Invest 1981; 68: 819–22
- Scherr DS, Pitts WR. The non steroidal effects of diethylstilbesterol: the rationale for androgen deprivation therapy without oestrogen deprivation in the treatment of prostate cancer. J Urol 2003; 170: 1703–8
- Bolla M, Gonsalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295–300
- Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–7
- Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, et al. Society of Urologic Oncology position statement redefining the management of hormone-refractory prostate carcinoma. Cancer 2005; 103: 11–21
- Newling D, Fossa SD, Andersson L, Abrahamsson PA, Aso Y, Eisenberger MA, et al. Assessment of hormone refractory prostate cancer. Urology 1997; 49: 46–53
- Gleave ME, Small EJ. Androgen deprivation therapy for prostate cancer. Report to the nation on prostate cancer 2004, PR Caroll, WG Nelson. Medscape, Elmwood Park, NJ 2004; 27–36
- Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006; 175: 27–34
- Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol 1997; 57: 929–34
- Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276–308
- Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med 2005; 351: 1502–12
- Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2005; 351: 1513–20